VNDA Logo

Vanda Pharmaceuticals Inc. (VNDA) 

NASDAQ
Market Cap
$286.88M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
756 of 774
Rank in Industry
420 of 432

Largest Insider Buys in Sector

VNDA Stock Price History Chart

VNDA Stock Performance

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment …

Insider Activity of Vanda Pharmaceuticals Inc.

Over the last 12 months, insiders at Vanda Pharmaceuticals Inc. have bought $0 and sold $552,533 worth of Vanda Pharmaceuticals Inc. stock.

On average, over the past 5 years, insiders at Vanda Pharmaceuticals Inc. have bought $0 and sold $3.51M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 11,170 shares for transaction amount of $100,156 was made by Flynn James E (10 percent owner) on 2015‑12‑16.

List of Insider Buy and Sell Transactions, Vanda Pharmaceuticals Inc.

2024-11-14Saledirector
5,000
0.0086%
$5.17$25,8630.00%
2024-07-29SaleSVP, CFO & Treasurer
2,251
0.0038%
$5.92$13,327-16.75%
2024-03-05SalePresident and CEO
24,288
0.0421%
$4.13$100,273+20.94%
2024-03-05SaleSVP, Business Development
8,684
0.0151%
$4.13$35,884+20.94%
2024-03-05SaleSVP, CFO & Treasurer
8,902
0.0157%
$4.20$37,411+20.94%
2024-03-05SaleSVP & General Counsel
8,941
0.0157%
$4.18$37,396+20.94%
2024-03-05SaleSVP, Chief Marketing Officer
9,229
0.0163%
$4.21$38,830+20.94%
2024-03-04SalePresident and CEO
30,884
0.0534%
$4.24$131,066+16.59%
2024-03-04SaleSVP, Business Development
8,727
0.0153%
$4.30$37,495+16.59%
2024-03-04SaleSVP, CFO & Treasurer
5,798
0.0106%
$4.48$25,982+16.59%
2024-03-04SaleSVP & General Counsel
8,147
0.0146%
$4.41$35,917+16.59%
2024-03-04SaleSVP, Chief Marketing Officer
7,498
0.0135%
$4.41$33,091+16.59%
2023-08-21SaleSVP, Chief Marketing Officer
3,724
0.0064%
$5.84$21,748-26.09%
2023-08-10Saledirector
6,500
0.0114%
$6.05$39,349-27.08%
2023-07-28SaleSVP, CFO & Treasurer
2,212
0.0038%
$6.30$13,945-25.93%
2023-06-15SaleSVP, CFO & Treasurer
16,000
0.0279%
$6.29$100,710-29.57%
2023-06-13SaleSVP & General Counsel
14,600
0.0257%
$6.56$95,754-31.65%
2023-03-03SalePresident and CEO
22,538
0.0388%
$6.25$140,876-19.78%
2023-03-03SaleSVP, Business Development
8,268
0.0143%
$6.26$51,791-19.78%
2023-03-03SaleSVP, CFO & Treasurer
5,968
0.0103%
$6.28$37,499-19.78%

Insider Historical Profitability

138.94%
Polymeropoulos Mihael HristosPresident and CEO
1871730
3.2101%
$4.92552<0.0001%
TANG KEVIN C10 percent owner
2715852
4.6578%
$4.9268+419.54%
Flynn James E10 percent owner
693171
1.1888%
$4.9255+15.47%
Kelly James PatrickEVP & Chief Financial Officer
186869
0.3205%
$4.92114<0.0001%
Clark William DSr. VP, Chief Business Officer
168279
0.2886%
$4.92110<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$33.45M13.998.14M-2.47%-$848,657.44<0.01
Renaissance Technologies$17.57M7.354.28M+16.15%+$2.44M0.03
The Vanguard Group$13.96M5.843.4M-1.75%-$248,671.42<0.0001
Acadian Asset Management$9.74M4.072.37M+4.74%+$440,510.400.03
D. E. Shaw & Co.$7.41M3.11.8M-14.64%-$1.27M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.